Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2′-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4- (2-oxazolyl)[1,1′-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ETA selective antagonist

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 125-137

  Murugesan, Natesan ^a   Gu, Zhengxiang ^a   Spergel, Steven ^a   Young, Marian ^a   Chen, Ping ^a   Mathur, Arvind ^a   Leith, Leslie ^a   Hermsmeier, Mark ^a   Liu, Eddie C K ^a   Zhang, Rongan ^a   Bird, Eileen ^a   Waldron, Tom ^a   Marino, Anthony ^a   Koplowitz, Barry ^a   Humphreys, W Griffith ^a   Chong, Saeho ^a   Morrison, Richard A ^a   Webb, Maria L ^a   Moreland, Suzanne ^a   Trippodo, Nick ^a   Barrish, Joel C ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 193884; BMS 207940; ENDOTHELIN A RECEPTOR ANTAGONIST; N [[2' [[(4,5 DIMETHYL 3 ISOXAZOLYL)AMINO]SULFONYL] 4 (2 OXAZOLYL)(1,1' BIPHENYL) 2 YL]METHYL] N,3,3 TRIMETHYLBUTANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; NONHUMAN; PRESSOR RESPONSE; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CACO-2 CELLS; CAROTID ARTERIES; CHO CELLS; CRICETINAE; HUMANS; ISOXAZOLES; MACACA FASCICULARIS; MALE; MUSCLE CONTRACTION; OXAZOLES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0037413530     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020289q     Document Type: Article

References (24)

1. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London) 1988, 332, 411-15.
2. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-7.
3. Wu-Wong, J. R.; Opgenorth, T. J. The roles of endothelins in proliferation, apoptosis, and angiogenesis. Handb. Exp. Pharmacol. 2001, 152, 299-322.
4. Rubanyi, G. M.; Polokoff, M. A. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 1994, 46, 325-415.
5. Schiffrin, E. L.; Touyz, R. M. Vascular biology of endothelin. J. Cardiovasc. Pharmacol. 1998, 32 (Suppl. 3), S2-S13.
6. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 1990, 348, 730-2.
7. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature (London) 1990, 348, 732-5.
8. Warner, T. D.; Mitchell, J. A.; De Nucci, G.; Vane, J. R. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J. Cardiovasc. Pharmacol. 1989, 13 (suppl. 5), S85-88.
9. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; Nishikibe, M.; Yano, M. Biochemical and pharmacological profile of a potent and selective endothelinB-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4892-4896.
10. Elliott, J. D.; Ohlstein, E. H.; Peishoff, C. E.; Ellens, H. M.; Lago, M. A. Endothelin receptor antagonists. Pharm. Biotechnol. 1998, 11, 113-129.
11. Spieker, L. E.; Noll, G.; Ruschitzka, F. T.; Luscher, T. F. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? J. Am. Coll. Cardiol. 2001, 37, 1493-1505.
12. Dao, H. H.; Moreau, P. An update on the status of endothelin receptor antagonists for hypertension. Expert Opin. Invest. Drugs 2001, 10, 1937-1946.
13. Luscher, T. F.; Barton, M. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102 (19), 2434-2440
14. Seed, A.; Love, M. P.; McMurray, J. J. V. Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Rev. 2001, 6 (4), 317-323.
15. Murugesan, N.; Gu, Z.; Stein, P. D.; Bisaha, S.; Spergel, S.; Girotra, R.; Lee, V. G.; Lloyd, J.; Misra, R. N.; Schmidt, J.; Mathur, A.; Stratton, L.; Kelly, Y. F.; Bird, E.; Waldron, T.; Liu, E. C. K.; Zhang, R.; Lee, H.; Serafino, R.; Abboa-Offei, B.; Mathers, P.; Giancarli, M.; Seymour, A. A.; Webb, M. L.; Moreland, S.; Barrish, J. C.; Hunt, J. T. Biphenylsulfonamide endothelin antagonists: Structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2′-amino-N-(3,4-dimethyl-5-isoxazolyl)-4′- (2-methylpropyl)[1,1′-biphenyl]-2-sulfonamide (BMS-187308). J. Med. Chem. 1998, 41, 5198-5218.
16. Murugesan, N.; Gu, Z.; Stein, P. D.; Spergel, S.; Mathur, A.; Leith, L.; Liu, E. C. K.; Zhang, R.; Bird, E.; Waldron, T.; Marino, A.; Morrison, R. A.; Webb, M. L.; Moreland, S.; Barrish, J. C. Biphenylsulfonamide endothelin receptor antagonists. 2: Discovery of 4′-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETA antagonists. J. Med. Chem. 2000, 43, 3111-3117.
17. Murugesan, N.; Gu, Z.; Stein, P. D.; Bisaha, S.; Spergel, S.; Liu, E. C. K.; Zhang, R.; Webb, M. L.; Moreland, S.; Barrish, J. C. Biphenylsulfonamide endothelin receptor antagonists. 3. structure-activity relationship of 4′-heterocyclic biphenylsulfonamides. Bioorg. Med. Chem. Lett. 2002, 12, 517.
18. Murugesan, N. Discovery ofBMS-193884, a potent and selective ETA receptor antagonist. Book of Abstracts, 219th American Chemical Society National Meeting, San Francisco, CA, 2000; American Chemical Society: Washington, DC, MEDI-164.
19. Scheinmann, F.; Stachulski, A. V. Convenient synthesis of a novel γ-aminobutyric acid analog: 4-amino-2,2-dimethylbutanoic acid. J. Chem. Res., Synop. 1993, 10, 414-15.
20. Dannhardt, G. 1-(Δ1′-Pyrrolin-2′-yl)-Δ2-pyrrolines. Arch. Pharm. (Weinheim, Ger.) 1978, 311, 294-302.
21. Padwa, A.; Coats, S. J.; Semones, M. A. Details associated with the bimolecular 1,4-dipolar cycloaddition reaction of cross-conjugated heteroaromatic betaines. Tetrahedron 1995, 51 (24), 6651-68.
22. Murugesan, N.; Barrish, J. C.; Spergel, S. H. Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists. US Patent 5846990; Chem. Abstr. 1998, 130, 52406.
23. Konoike, T.; Kanda, Y.; Araki, Y. Directed lithiation of N-(tert-butoxycarbonyl)aminoisoxazole: Synthesis of 4-substituted aminoisoxazoles. Tetrahedron Lett. 1996, 37, 3339-3342.
24. Clozel, M.; Breu, V.; Gray, G. A.; Kalina, B.; Loffler, B. M.; Burri, K.; Cassal, J. M.; Hirth, G.; Muuler, M.; Neidhart, W.; Ramuz, H. Pharmacological chacterization of Bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 1994, 270, 228-235.